# Open-Label Extension Protocol to SNK01-AD01 Study

> **NCT07228078** · PHASE2 · RECRUITING · sponsor: **NKGen Biotech, Inc.** · enrollment: 30 (estimated)

## Conditions studied

- Alzheimer Disease

## Interventions

- **BIOLOGICAL:** SNK01

## Key facts

- **NCT ID:** NCT07228078
- **Lead sponsor:** NKGen Biotech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-30
- **Primary completion:** 2028-04
- **Final completion:** 2028-04
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07228078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07228078, "Open-Label Extension Protocol to SNK01-AD01 Study". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07228078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*